Sexual Health & Reproductive Function
Sexual health peptides include the FDA-approved Bremelanotide (PT-141) for HSDD, gonadorelin for hormonal support, and kisspeptin for HPG axis regulation. Evidence ranges from Phase III RCTs to research-stage compounds.
Relevant Peptides
FDA-approved Vyleesi for HSDD in premenopausal women.
Phase II LH/testosterone stimulation in humans.
FDA-approved; TRT adjunct for fertility preservation.
FDA-approved GnRH agonist; hormone suppression.
Unapproved; significant side effect burden.
The TRT Context
A growing use case for gonadorelin and kisspeptin is as adjuncts to testosterone replacement therapy (TRT) — maintaining HPG axis function and fertility in men receiving exogenous testosterone, which otherwise suppresses natural hormone production.
Gonadorelin has FDA approval and 503A listing, making it the most accessible legal option. Kisspeptin has compelling Phase II data but no US approval.
PT-141 vs. PDE5 Inhibitors
PT-141 works centrally (brain, motivation/desire) while sildenafil/tadalafil work peripherally (blood vessel dilation). They address different aspects of sexual dysfunction — PT-141 is specifically relevant when desire/motivation is impaired, not just arousal/erection mechanics.
Stay current on peptide evidence
Weekly regulatory updates and study breakdowns. Free.